European Psychiatry - Volume 41 - April 2017

210 / 916

S206 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S170–S237
EW0294
Use of novel psychoactive substances
and induced psychiatric symptoms:
Outcomes from the Eivissa Project
G. Martinotti ∗, C. Montemitro , M. Corbo , F. Sarchione ,
E. Cinosi , A. Pasquini , V. Mancini , C. Merino del Villar
1 Neuroscience and Imaging, University G. d’Annunzio, Chieti, Italy
2 Department of Psychiatry, Hospital Can Misses, Ibiza, Spain
∗ Corresponding author.
Introduction Polydrug abuse seems to be especially popular in
Ibiza, an important market for new psychoactive substances (NPS).
The misuse of psychoactive substances can lead to serious psychi-
atric symptoms.
Aims To evaluate symptoms induced by NPSs and other club
drugs, correlating with the main classes of drugs.
Methods Ninety subjects (M/F 59/31) admitted in the Psychiatric
Unit of Can Misses Hospital (Ibiza) referring a recent intake of sub-
stances were enrolled. The following scales were administered:
TLFB (Timeline follow-back); Positive and Negative Symptoms
Scale (PANSS); Symptom checklist-90 (SCL-90) ; Young Mania Rat-
ing Scale (YMRS) ; Hamilton Depression Scale (HAM-D); Hamilton
Anxiety Scale (HAM-A); Modified Overt Aggression Scale (MOAS);
Columbia Suicide Severity Rating Scale (C-SSRS).
Results Polydrug abuse was reported by 67.4% of the sample;
the sample was grouped by the main preferred substance in
THC-, stimulants-, and depressors-users. The majority of patients
reported a previous psychiatric history. Positive symptoms resulted
to be higher among THC-users ( P < .05). Anxiety evaluated by
SCL-90 was prevalent in the group of Depressors-users (P < .05).
The scores of MOAS and SCL-90 subscale for hostility/aggression
resulted to be significantly (P< .01) greater in the THC-users group.
Conclusions Some specific psychiatric symptoms are character-
istic of some classes of substances and may help to identify them
when a urine sample is not available. The possibility to develop
psychiatric symptoms after a recent drug use is more common in
two situations: (1) patients with a previous psychiatric history; (2)
subjects with a history of very strong substance use.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
e-poster walk: Bipolar disorders – Part 2
EW0295
The concentration of the factors
involved in trafficking of stem cells in
long-term treated bipolar disorder
patients
J. Kucharska-Mazur ∗, A. Reginia , M. Jabło ´nski ,
B. Doł˛egowska , J. Rybakowski , M.Z. Ratajczak ,
J. Samochowiec
1 Department of Psychiatry, Pomeranian Medical University,
Szczecin, Poland
2 Department of Microbiology and Immunological Diagnostics,
Pomeranian Medical University, Szczecin, Poland
3 Department of Adult Psychiatry, University of Medical Sciences,
Pozna´n, Poland
4 University of Louisville, Stem Cell Biology Program at the James
Graham Brown Cancer Center, USA
∗ Corresponding author.
Introduction After analysis of biological and pharmacological
data, we formulated the hypothesis that the factors involved in
trafficking of stem cells could be engaged in aetiology of bipolar
disorder (BP).
Aims In this study, we considered the role of comple-
ment cascade proteins, stromal derived factor-1 (SDF-1), and
sphingosine-1-phosphate (S1P) in long-term treated BP.
Methods A group of 30 patients with BP, without the history of
lithium treatment, was examined in remission and compared with
a group of 30 healthy volunteers. In peripheral blood, we have
analysed the concentration of stromal derived factor-1 (SDF-1),
sphingosine-1-phosphate (S1P), and some proteins of the comple-
ment cascade (C3a, C5a, C5b-9).
Results Peripheral blood concentration of C3a, C5a, C5b-9 and
SDF-1 was significantly higher in BP group compared to control
group. The concentration of S1P does not distinguish BP patients
from controls.
Conclusion Our results suggest the possible role of the regenera-
tion system in aetiology of BP.
This work was supported by grant POIG.01.01.02-00-109/09.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0296
Five-year course of bipolar disorder
following treatment of first manic
episode with risperidone versus
olanzapine: A retrospective review
K. Kulkarni ∗, G. Devasthali , A. Purty , M. Kesavan , J. Reddy ,
S. Jain
Psychiatry, National Institute of Mental Health & Neurosciences,
Bangalore, India
∗ Corresponding author.
Objective Contemporary treatment guidelines recommend use of
second-generation antipsychotics (SGAs) either as mono therapy
or in combination with mood stabilizers as first-line treatment.
While these drugs have been established to have superior effi-
cacy compared to placebo, there is very less data comparing these
antipsychotics with one another. We sought to study differences
in the five-year outcome of first episode of mania (FEM) treated
with olanzapine or risperidone, either alone or in combinationwith
mood stabilizer.
Methods We conducted a retrospective chart review of patients
diagnosed with FEM (ICD-10) in the year 2008 (n = 88) at our cen-
tre. We selected the data of patients prescribed either olanzapine
or risperidone for the purpose of this analysis. We extracted data
about time to recovery and recurrence after FEM, total episodes,
drug compliance and response, and number of follow-up visits
from 2008 to 2013. The study was approved by the Institute Ethics
Committee.
Results A total of 88 patients received diagnosis of FEM in the
year 2008, of which 50 (56.8%) received risperidone and 35 (39.8%)
received olanzapine. The two groups were comparable in socio-
demographic and clinical symptomatology of FEM (all P > 0.08).
Complete recovery was significantly more in the olanzapine group
than the risperidone group ( 2 = 4.84, P < 0.05).
Conclusion Our study indicates that risperidone and olanzapine,
either alone or in combination with mood stabilizers have a similar
impact on the five-year course of BD following a firstmanic episode.
However, olanzapine is associated with more complete recovery
from FEM than risperidone.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.